Follow Michael A Robinson Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
As members of Congress burned the midnight oil to pass a $1.3 trillion budget bill by their March 23 deadline, they attached a recurring "rider" that bans the U.S. Department of Justice from using funds to interfere with medical marijuana in states that have legalized it.
U.S. President Donald Trump went on to sign that $1.3 trillion spending measure, which protects medical marijuana businesses through at least Sept. 30. And this time he didn't include a signing statement reserving his right to ignore that rider, which he did last May.
In other words, we just got another "green light" from Washington.
Now, this isn't exactly a slam dunk for the industry: Some lawmakers wanted to extend these protections to cover recreational marijuana as well, but the U.S. House Rules Committee blocked that effort along a party-line vote on March 21.
Still, these moves by federal lawmakers give you a sense of their seriousness here…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.